Educational program to reduce major bleeding in patients undergoing percutaneous coronary interventions and receiving abciximab.
Dobesh
Paul P
PP
Division of Pharmacy, St. Louis College of Pharmacy (SLCP), 4588 Parkview Place, St. Louis, MO 63110, USA. pdobesh@stlcop.edu
Lakamp
Jonathan E
JE
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000191:economics / Q000517:prevention & control*; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077284:Abciximab